A new drug that could get rid of the undesirable fat under the chin has been unanimously approved by the Food and Drug Administration (FDA) dermatologists` board. The injection was developed by Kythera Biopharmaceuticals and its aim is to remove the so called double chin,that troubles a lot of people.
The FDA recommended the new drug for approval after a series of tests. Kythera Biopharmaceuticals have shown though a clinical trial to which more than 2,500 people participated, that their substance, ATX-101, has satisfactory effects, and that it can permanently reduce the emergence chance of a second chin. Out of the participants to the clinical study, 87 per cent said they have observed a compelling decrease in fat. 96 per cent showed betterment in their chin and neck definition.
ATX-101 uses a synthetic version of an acid that the intestinal bacteria secretes to dissolve fat, during the process of digestion. This synthetic bile acid is called deoxycholic acid (DCA). Researchers say that the treatment consists in a set of injections executed monthly. They estimate that a maximum of 50 injections will be needed in order to get rid of the unwanted fat under your chin, administered in 6 sessions.
Still, the new drug hasn`t got the final approval, so you won`t be able to find it in drugstores or get a recommendation from your dermatologist yet. However, in most cases, new drugs that are recommended for approval enter the pharmaceutical market in the end. It wouldn`t be a surprise if the ATX-101 will be demanded in high amounts. This was the case of other pharmaceutical products, like Botox, which deal with aesthetic problems. More than 3.5 million people did Botox treatments last year, shows a study published on Wednesday by the American Society for Aesthetic Plastic Surgery.
The study also reveals that Americans are highly interested in fat reduction treatments that avoid surgical interventions. The rate of people interested in this area of pharmaceutics rose 43 per cent from 2013 to 2014. This idea is also supported by the fat that people spent more than 4.8 billion dollars in 2014, on nonsurgical aesthetic treatments.
Kythera Biopharmaceuticals have stated that they are ready to raise 125 million dollars to continue the developments of ATX-101 treatments and to fund its marketing. The company added that regulatory filings will exist in Canada, Australia and Switzerland.
Dr. Leo McCafferty, who is a plastic surgeon, highlights the fact that the treatment will be accessible, and many doctors will be able to offer it.
“It doesn’t involve a very expensive piece of equipment, like a laser which might cost $100,000. It involves a syringe, the product and the needle.”
Dr. McCafferty says. He added that the ATX-101 will be a valuable tool, but it won`t work as a panacea for all double chin cases.
If the Food and Drug Administration panel will give their final approval for the new drug, it will be a less expensive, more comfortable alternative to plastic surgery. Right now, the only nonsurgical options cost from 800 to 2,500 dollars.
Image Source: The Daily Beast
Latest posts by Nathan Fortin (see all)
- The End of Life Option Act Already Used by 111 People - Jun 28, 2017
- Senate Decided to Kill Rule that Promotes Retirement Plans - Apr 1, 2017
- BlackRock Is Turning to Robots for Improved Stocks - Mar 30, 2017